

Hydroxypropyl methyl cellulose phthalate (HP50)	270 g
Triacetin	30 g
Acetone	900 g
Ethanol	1800 g

600 g of this enteric coating solution are used for 1 kg of capsules (ca. 2400). The amount of coating applied to each capsule is about 25 mg giving a film thickness of 5–6 mg/cm<sup>2</sup>.

We claim:

1. A pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to prevent release of the mycophenolate salt in the stomach and to release the mycophenolate salt in the upper part of the intestinal tract.

2. A pharmaceutical composition comprising an enteric coated pharmaceutically acceptable mycophenolate salt.

3. A method of immunosuppressing a subject which comprises administering a therapeutically effective amount of enteric coated pharmaceutically acceptable mycophenolate salt or a composition of claim 1 to a subject in need of

such immunosuppression, optionally with the simultaneous or separate administration of another immunosuppressant.

4. A composition containing an enteric coated pharmaceutically acceptable mycophenolate salt or a composition of claim 1 and another immunosuppressant for simultaneous, sequential or separate administration.

5. A pharmaceutical composition according to claim 1 wherein the mycophenolate salt is a mono-sodium salt.

6. A pharmaceutical composition according to claim 2 wherein the mycophenolate salt is a mono-sodium salt.

7. A method according to claim 3 wherein the mycophenolate salt is a mono-sodium salt.

8. A method according to claim 3 wherein said another immunosuppressant is cyclosporin.

9. A pharmaceutical composition according to claim 4 wherein the mycophenolate salt is a mono-sodium salt.

10. A pharmaceutical composition according to claim 9 wherein said another immunosuppressant is cyclosporin.

11. A pharmaceutical composition according to claim 4 wherein said another immunosuppressant is cyclosporin.

\* \* \* \* \*